General Information of Drug (ID: DMDTGWQ)

Drug Name
GMI-1271 Drug Info
Synonyms Uproleselan
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
PubChem CID
71600085
CAS Number
CAS 1983970-12-2
TTD Drug ID
DMDTGWQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting E-selectin (SELE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GMI-1070 DMJ432G Asthma CA23 Phase 3 [4]
CY-1503 DML906E Hypertension BA00-BA04 Phase 2/3 [5]
Bimosiamose DM0TH9A Atopic dermatitis EA80 Phase 2a [6]
GMI-1359 DML1KSA Breast cancer 2C60-2C65 Phase 1 [7]
PF-07209326 DM7YRAL Sickle-cell disorder 3A51 Phase 1 [8]
GI-270384X DM3KN2Q Inflammatory bowel disease DD72 Terminated [9]
Fucose DMAHMSV N. A. N. A. Investigative [10]
O-Sialic Acid DMCAR7B Discovery agent N.A. Investigative [11]
Efomycine M DMOKX76 Discovery agent N.A. Investigative [12]
1na DM0A1YI Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E-selectin (SELE) TTAU4D6 LYAM2_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of glycomimetics.
4 Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
5 Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
6 Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
7 Clinical pipeline report, company report or official report of GlycoMimetics.
8 ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
9 Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
12 Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.